Daeyang E&C

Aprogen is a prominent South Korean biotechnology company specializing in the development and manufacturing of biosimilars and novel antibody therapeutics. Originally founded as Daeyang E&C, the company transitioned from healthcare devices to advanced biotechnology through a series of strategic mergers, eventually becoming South Korea's first biotech 'unicorn.' The company is best known for its proprietary perfusion-based continuous manufacturing platform, which significantly enhances production efficiency for complex biologics. Its pipeline includes biosimilars for major drugs such as Remicade, Herceptin, and Rituxan, as well as innovative bispecific antibodies targeting oncology and inflammatory conditions. Aprogen operates one of the world's largest perfusion-based manufacturing facilities in Osong, South Korea, positioning itself as a key player in the global biopharmaceutical supply chain.